A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
Withdrawn
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase 3
2015-11-01
This study will be a double-blind, randomized, multicenter trial to assess the safety and
efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of
azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12
hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of
Community Acquired Bacterial Pneumonia.
More than 40% of patients presenting with acute bacterial skin and skin structure infection
(ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for
intravenous antibiotics. There is growing evidence to suggest that many hospital admissions
for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative
treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient
follow-up, such an alternative hospital avoidance strategy has the potential to improve
quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited
inpatient healthcare resources.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
